Dopamine Agonists Market

Dopamine agonists (DA) are medications that work by imitating the actions of dopamine when levels are low. These medications improve condition-related symptoms by fooling the brain into thinking dopamine is available.

Dopamine Agonists Market contains market size and forecasts of Dopamine Agonists in global, including the following market information:

• Global Dopamine Agonists Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Dopamine Agonists Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Dopamine Agonists companies in 2021 (%)

The global Dopamine Agonists market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Ergotamine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Dopamine Agonists include Pfizer, GSK, Roche, Merck, UCB, Teva Pharmaceutical Industries Ltd, ACADIA Pharmaceuticals Inc, Impax Laboratories and AbbVie, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

surveyed the Dopamine Agonists manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Dopamine Agonists Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Dopamine Agonists Market Segment Percentages, by Type, 2021 (%)

• Ergotamine
• Non-ergotamine

Global Dopamine Agonists Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Dopamine Agonists Market Segment Percentages, by Application, 2021 (%)

• Parkinson's
• Restless Legs Syndrome

Global Dopamine Agonists Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Dopamine Agonists Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Dopamine Agonists revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Dopamine Agonists revenues share in global market, 2021 (%)
• Key companies Dopamine Agonists sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Dopamine Agonists sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• GSK
• Roche
• Merck
• UCB
• Teva Pharmaceutical Industries Ltd
• ACADIA Pharmaceuticals Inc
• Impax Laboratories
• AbbVie
• Boehringer Ingelheim
• Otsuka Pharmaceutical Co
• Kissei Pharmaceutical Co